NDAORALTABLET
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTONEL WITH CALCIUM is a copackaged combination of risedronate sodium (a bisphosphonate) and calcium carbonate designed to treat osteoporosis by inhibiting bone resorption and providing essential calcium supplementation. The product addresses the need for simplified dosing and improved compliance in patients requiring both therapeutic and supplemental agents. This oral tablet formulation targets postmenopausal women and other osteoporosis patients who require concurrent bone-protective therapy and calcium replacement.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and a transition from growth-focused to defensive commercial strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ACTONEL WITH CALCIUM offers limited career growth in a mature, LOE-approaching product; roles are primarily defensive and focused on maximizing remaining exclusivity and managing competitive/generic transition. Career advancement will depend on lateral movement into new product lines or shift into specialty roles such as outcomes research or market access strategy.
Brand Manager
Worked on ACTONEL WITH CALCIUM (COPACKAGED) at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.